MetabolicIn Clinical Trials

Apraglutide

Subcutaneous injection

Overview

Apraglutide is a long-acting glucagon-like peptide-2 (GLP-2) receptor agonist designed to promote intestinal growth and improve absorption in patients with short bowel syndrome. The peptide analogue shares structural homology with native GLP-2 but incorporates modifications that extend its half-life and enhance resistance to dipeptidyl peptidase-4 degradation.

Mechanism of Action

By binding to GLP-2 receptors in the intestinal epithelium, apraglutide stimulates crypt cell proliferation and reduces gastric emptying and secretion, supporting adaptive intestinal function..

Research Summary & Key Findings

Phase 3 trials in adults with short bowel syndrome dependent on parenteral support have demonstrated significant reductions in parenteral nutrition volume requirements compared to placebo. The compound has been studied primarily in patients with remnant colon or jejunostomy configurations, with published data appearing in Gastroenterology and related specialty journals since 2020.

Clinical Status

In Clinical Trials

Apraglutide is currently undergoing clinical trials. It is not yet FDA-approved and is available only through clinical research settings or investigational protocols.

Administration Routes

Subcutaneous injection

Related Peptides in Metabolic

Find a Provider

Find a verified provider who offers Apraglutide therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Apraglutide.

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.